EA201070216A1 - Окисленный авидин с большим временем удержания в обработанной им ткани - Google Patents

Окисленный авидин с большим временем удержания в обработанной им ткани

Info

Publication number
EA201070216A1
EA201070216A1 EA201070216A EA201070216A EA201070216A1 EA 201070216 A1 EA201070216 A1 EA 201070216A1 EA 201070216 A EA201070216 A EA 201070216A EA 201070216 A EA201070216 A EA 201070216A EA 201070216 A1 EA201070216 A1 EA 201070216A1
Authority
EA
Eurasian Patent Office
Prior art keywords
avidins
oxidation
tissue
brachytherapy
groups
Prior art date
Application number
EA201070216A
Other languages
English (en)
Other versions
EA017017B1 (ru
Inventor
Рита Де Сантис
Карло Антонио Нуццоло
Original Assignee
Сигма-Тау Индустрие Фармасьютике Риуните С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. filed Critical Сигма-Тау Индустрие Фармасьютике Риуните С.П.А.
Publication of EA201070216A1 publication Critical patent/EA201070216A1/ru
Publication of EA017017B1 publication Critical patent/EA017017B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Optics & Photonics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В настоящем изобретении описаны химически модифицированные авидины, имеющие большую стабильность в обработанной ими ткани по сравнению с авидином дикого типа. Окисление авидина проводят окислением с периодатом в присутствии низкоаффинного лиганда НАВА, который, занимая участки связывания биотина, предупреждает денатурацию белка в ходе стадии окисления. В результате окисления периодатом при разрыве маннозного кольца образуются СНО-группы, которые при инъекции в ткань вступают в реакцию с NH-группами ткани, образуя стабильные шиффовы основания. Заякоренные авидины сохраняют способность связывать биотинилированные агенты, имеющие терапевтическую активность, такие как радиоактивно меченные биотины, стволовые клетки и соматические клетки, используемые для брахитерапии, подобной радионуклидной терапии с интраоперативным авидинированием для (IART®), или для брахитерапии дегенеративных или генетических болезней.
EA201070216A 2007-08-02 2008-07-16 Окисленный авидин с большим временем удержания в обработанной им ткани EA017017B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07113733 2007-08-02
EP08157473 2008-06-03
PCT/EP2008/059260 WO2009016031A1 (en) 2007-08-02 2008-07-16 Oxidized avidin with high residency time in the treated tissues

Publications (2)

Publication Number Publication Date
EA201070216A1 true EA201070216A1 (ru) 2010-08-30
EA017017B1 EA017017B1 (ru) 2012-09-28

Family

ID=39734214

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070216A EA017017B1 (ru) 2007-08-02 2008-07-16 Окисленный авидин с большим временем удержания в обработанной им ткани

Country Status (26)

Country Link
US (1) US8562947B2 (ru)
EP (1) EP2185203B1 (ru)
JP (1) JP5577248B2 (ru)
KR (1) KR101544628B1 (ru)
CN (1) CN101772353B (ru)
AR (1) AR067771A1 (ru)
AU (1) AU2008281901B2 (ru)
BR (1) BRPI0815050B8 (ru)
CA (1) CA2694391C (ru)
DK (1) DK2185203T3 (ru)
EA (1) EA017017B1 (ru)
ES (1) ES2625815T3 (ru)
HK (1) HK1145290A1 (ru)
HR (1) HRP20170735T1 (ru)
HU (1) HUE032093T2 (ru)
IL (1) IL203321A (ru)
LT (1) LT2185203T (ru)
MX (1) MX2010001302A (ru)
MY (1) MY155347A (ru)
NZ (1) NZ582711A (ru)
PL (1) PL2185203T3 (ru)
PT (1) PT2185203T (ru)
SG (1) SG183076A1 (ru)
SI (1) SI2185203T1 (ru)
TW (1) TWI441650B (ru)
WO (1) WO2009016031A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2591524C2 (ru) * 2010-12-28 2016-07-20 Джапан Тобакко Инк. Модифицированный тамавидин

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9872831B2 (en) 2011-08-02 2018-01-23 Alfasigma S.P.A. Pharmaceutical composition of oxidised avidin suitable for inhalation
JP2014001204A (ja) * 2012-05-23 2014-01-09 Kumamoto Univ 腫瘍細胞選択的抗がん剤
EP2941243A4 (en) 2013-01-04 2016-09-14 Massachusetts Inst Technology SURFACE BINDING IN THE ADMINISTRATION OF A MEDICAMENT ON NANOPARTICLE BASE IN A TISSUE
EP3316871A4 (en) 2015-06-30 2019-02-20 The Trustees of Columbia University in the City of New York TALKED COMPOSITION AND USES THEREOF
US20200179530A1 (en) * 2016-05-19 2020-06-11 University Of Miami Targeted delivery of therapeutic agents and imaging reagents to pancreatic cancer cells
EP3857226B1 (en) * 2018-09-25 2023-11-15 Siemens Healthcare Diagnostics Inc. Methods and compositions for removing biotin interference from assays using conjugated molecular traps

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0733066B1 (en) * 1993-12-07 2003-11-19 NeoRx Corporation Pretargeting methods and compounds
US5716594A (en) * 1994-06-06 1998-02-10 The Jmde Trust Biotin compounds for targetting tumors and sites of infection
US8021667B2 (en) * 1994-11-16 2011-09-20 Macfarlane Burnet Institute For Medical Research And Public Health Ltd Compositions for immunotherapy and uses thereof
WO2000027814A1 (en) * 1998-11-10 2000-05-18 Yeda Research And Development Co. Ltd. Avidin derivatives and uses thereof
US7001994B2 (en) * 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US20040101901A1 (en) * 2002-11-27 2004-05-27 Piotr Tabaczewski Novel lipophilic complexes for insertion of receptors into lipid membranes
ITRM20030196A1 (it) 2003-04-24 2004-10-25 Sigma Tau Ind Farmaceuti Uso di reagenti per la preparazione di un medicamento

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2591524C2 (ru) * 2010-12-28 2016-07-20 Джапан Тобакко Инк. Модифицированный тамавидин

Also Published As

Publication number Publication date
KR101544628B1 (ko) 2015-08-17
TW200920403A (en) 2009-05-16
SG183076A1 (en) 2012-08-30
LT2185203T (lt) 2017-06-12
AU2008281901B2 (en) 2013-08-15
MY155347A (en) 2015-10-15
IL203321A (en) 2014-05-28
EA017017B1 (ru) 2012-09-28
US8562947B2 (en) 2013-10-22
BRPI0815050B1 (pt) 2020-01-28
CA2694391A1 (en) 2009-02-05
CN101772353B (zh) 2013-03-06
BRPI0815050A2 (pt) 2015-02-10
PL2185203T3 (pl) 2017-08-31
NZ582711A (en) 2011-10-28
EP2185203B1 (en) 2017-02-22
AU2008281901A1 (en) 2009-02-05
ES2625815T3 (es) 2017-07-20
JP5577248B2 (ja) 2014-08-20
HUE032093T2 (en) 2017-08-28
BRPI0815050B8 (pt) 2021-05-25
MX2010001302A (es) 2010-03-01
TWI441650B (zh) 2014-06-21
BRPI0815050A8 (pt) 2017-12-26
SI2185203T1 (sl) 2017-07-31
CA2694391C (en) 2019-02-26
US20100239497A1 (en) 2010-09-23
DK2185203T3 (da) 2017-06-06
HK1145290A1 (en) 2011-04-15
CN101772353A (zh) 2010-07-07
HRP20170735T1 (hr) 2017-07-28
PT2185203T (pt) 2017-06-02
EP2185203A1 (en) 2010-05-19
AR067771A1 (es) 2009-10-21
JP2010535166A (ja) 2010-11-18
WO2009016031A1 (en) 2009-02-05
KR20100051696A (ko) 2010-05-17

Similar Documents

Publication Publication Date Title
EA201070216A1 (ru) Окисленный авидин с большим временем удержания в обработанной им ткани
NO20070951L (no) Inhibitorer av angiopoientinlignende-4-protein, kombinasjoner og deres anvendelse.
EA201890903A1 (ru) Соединения пиридиловых ингибиторов передачи сигналов белком hedgehog, способ их получения, композиция и способы лечения рака и ингибирований ангиогенеза и сигнального пути hedgehog в клетках на их основе
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
ATE364698T1 (de) Neues, physiologisch aktives peptid und dessen verwendung
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
ATE421501T1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
ATE551060T1 (de) Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen
EA200600591A1 (ru) МОДУЛИРОВАНИЕ ЭКСПРЕССИИ eIF4E
WO2006120573A3 (en) Heterocyclic n-oxides as hypoxic selective protein kinase inhibitors
ATE434617T1 (de) 5-amino-4-hydroxy-7-(imidazo ä1,2-aü pyridin-6- ylmethyl)-8-methylnonamidderivate und verwandte verbindungen als renininhibitoren zur behandlung von bluthochdruck
MY140132A (en) Thiazolidin-4-one derivatives for use in the treatment of anemias
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
EA200600209A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,4-c]ПИРАЗОЛА, ОБЛАДАЮЩИЕ АКТИВНОСТЬЮ КАК ИНГИБИТОРЫ КИНАЗЫ
WO2004006838A3 (en) Novel kinases
HK1110802A1 (en) Use of nucleic acids in the preparation of a medicament for treating melanoma and the composition thereof
DE60019318D1 (de) Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe
WO2007080194A3 (en) Use of tpp ii inhibitors in combination with gamma-irradiation for the treatment of cancer
WO2004009024A3 (en) Modulation of protein kinase c-iota expression
DK1234025T3 (da) Humane enzymer fra metalloproteasefamilien
EA200702136A1 (ru) Композиции станнсопорфина и их применение
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
EA200700346A1 (ru) Бактериофаг- и профаг-специфические протеины в генной терапии рака
ATE516038T1 (de) Metallcluster-nanoverbindungen zur behandlung von tumorerkrankungen
ATE522625T1 (de) Verfahren und zusammensetzungen zur diagnose und behandlung von lungenkrebs mittels pdgfra-, kit- oder kdg-gen als genmarker

Legal Events

Date Code Title Description
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title